Pfizer Inc. (PFE)
Pfizer says patient dies after receiving hemophilia drug in trial
A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said.
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound
Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worrying execution risks tied to COVID franchise headwinds, loss of exclusivity, and the need for robust pipeline execution in oncology and obesity. Management's focus is on advancing multiple Phase III studies and commercializing new assets, but near-term valuation upside is unlikely until clearer growth visibility emerges.
Pfizer Stock Can Sink More. Here Is How
Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Pfizer (PFE) closed at $25.57, marking a -3.27% move from the previous day.
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Pfizer shares fall after it forecasts 2026 revenue below estimates
Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of COVID-19 products fall and generic competition rises. The company forecast revenue between $59.5 billion and $62.5 billion for 2026, with adjusted earnings per share of $2.80 to $3.
Here's why Pfizer is revising its revenue forecasts
The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.
Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings
Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is forecasting 2026 revenue of $61.6 billion and adjusted earnings of $3.05 a share.
Pfizer Adds to Its Big Bet on Weight Loss Drugs
Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included all of the Big Pharma mainstays.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
